Celldex Presents Barzolvolimab, CDX-622 Data
Analysis based on 6 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026
The positive clinical trial results for Celldex Therapeutics' drug candidates, Barzolvolimab and CDX-622, are expected to positively impact the company's stock price and investor confidence. These developments could lead to increased market share in the biotechnology and pharmaceuticals industries, particularly in treatments for allergic, inflammatory, and autoimmune disorders.
Celldex Therapeutics announced that it will present three sets of clinical trial data for its drug candidates, Barzolvolimab and CDX-622, at the European Academy of Allergy and Clinical Immunology Annual Congress in Istanbul, Turkey, from June 12-15, 2026. The presentations will include flash talks on Barzolvolimab's long-term treatment results in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU), highlighting its potential as a first-in-class treatment. Additionally, new first-in-human results from the Phase 1 trial of CDX-622, a novel bispecific antibody, will be presented, showcasing its potential to inhibit KIT signaling in mast cells and offer therapeutic benefits in inflammatory and fibrotic disorders. These presentations underscore Celldex Therapeutics' leadership in immunology and its commitment to developing life-changing therapies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard